Merck
CN
All Photos(2)

Documents

Safety Information

810158C

Avanti

16:0 Liss Rhod PE

Avanti Polar Lipids 810158C

Sign Into View Organizational & Contract Pricing
All Photos(2)
Synonym(s):
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt)
Empirical Formula (Hill Notation):
C64H105N4O14PS2
CAS Number:
384833-01-6
Molecular Weight:
1249.64
NACRES:
NA.25

Assay

>99% (TLC)

form

liquid

packaging

pkg of 1 × 1 mL (810158C-1mg)
pkg of 5 × 1 mL (810158C-5mg)

manufacturer/tradename

Avanti Polar Lipids 810158C

concentration

1 mg/mL (810158C-1mg)
1 mg/mL (810158C-5mg)

shipped in

dry ice

storage temp.

−20°C

General description

16:0 Liss Rhod PE is a fluorescent phospholipid.

Application

16:0 Liss Rhod PE has been used in the preparation of lipid-oil mixtures for fluorescent imaging and as a tracer lipid in process of unilamellar vesicles production. It is also suitable for fluorescent visualization of the phospholipids in tribiological investigation.

Packaging

5 mL Amber Glass Screw Cap Vial (810158C-1mg)
5 mL Amber Glass Screw Cap Vial (810158C-5mg)

Pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3

Target Organs

Central nervous system

Storage Class Code

6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK

WGK 3

Flash Point(F)

does not flash

Flash Point(C)

does not flash

Regulatory Information

易制毒化学品（2类）
危险化学品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Dynamic morphologies of microscale droplet interface bilayers
Mruetusatorn P, et al.
Soft Matter, 10(15), 2530-2538 (2014)
Tribological Analysis of UHMWPE Tibial Implants in Unicompartmental Knee Replacements: From Retrieved to In Vitro Studies
Sava MM, et al.
BioTechnology: An Indian Journal, 13, 1-15 (2018)
Kazunori Takano et al.
The EMBO journal, 27(21), 2817-2828 (2008-10-17)
Extended Fer-CIP4 homology (EFC)/FCH-BAR (F-BAR) domains generate and bind to tubular membrane structures of defined diameters that are involved in the formation and fission of endocytotic vesicles. Formin-binding protein 17 (FBP17) and Toca-1 contain EFC/F-BAR domains and bind to neural
Three dimensional (temperature-tension-composition) phase map of mixed DOPC-DPPC vesicles: Two solid phases and a fluid phase coexist on three intersecting planes
Chen D, et al.
Biochimica et Biophysica Acta - Biomembranes, 1838(11), 2788-2797 (2014)
Madi El-Haj et al.
Immunologic research, 67(4-5), 337-347 (2019-11-23)
The considerable variability of responses amongst subjects to disease triggers and immunotherapies is a major obstacle to designing better immune-based therapies. Therefore, development of patient-tailored precision medicine that improves the efficacy of immunomodulatory drugs is necessary. The individualized response to
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service